| Entry |
|
|---|
| Name |
|
|---|
| Formula |
C11H10BrN5
|
|---|
| Exact mass |
291.012
|
|---|
| Mol weight |
292.1346
|
|---|
| Structure |
   |
|---|
| Simcomp |
 |
|---|
| Remark |
| Product (DG00442): | D02076<JP/US> |
|
|---|
| Efficacy |
Antiglaucoma, alpha2-Adrenergic receptor agonist |
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
D DERMATOLOGICALS
D11 OTHER DERMATOLOGICAL PREPARATIONS
D11A OTHER DERMATOLOGICAL PREPARATIONS
D11AX Other dermatologicals
D11AX21 Brimonidine
D07540 Brimonidine (INN)
S SENSORY ORGANS
S01 OPHTHALMOLOGICALS
S01E ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01EA Sympathomimetics in glaucoma therapy
S01EA05 Brimonidine
D07540 Brimonidine (INN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adrenaline
ADRA2
D07540 Brimonidine (INN)
 |
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 17
1 C8x C 16.3100 -16.7300
2 C8x C 16.3100 -18.1300
3 N5x N 17.5000 -18.8300
4 C8y C 18.7600 -18.1300
5 C8y C 18.7600 -16.7300
6 N5x N 17.5000 -16.0300
7 C8x C 19.9500 -18.8300
8 C8x C 21.1400 -18.1300
9 C8y C 21.1400 -16.7300
10 C8y C 19.9500 -16.0300
11 N2x N 23.5900 -18.1300
12 C2y C 23.5900 -16.7300
13 N1b N 22.4000 -16.0300
14 C1x C 24.9200 -18.5500
15 C1x C 25.7600 -17.4300
16 N1x N 24.9200 -16.3100
17 X Br 19.9500 -14.6300
BOND 19
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 4 7 1
8 7 8 2
9 8 9 1
10 9 10 2
11 5 10 1
12 11 12 2
13 12 13 1
14 9 13 1
15 11 14 1
16 14 15 1
17 15 16 1
18 12 16 1
19 10 17 1
|
|---|
